4//SEC Filing
Primiano Christopher Brett 4
Accession 0001209191-20-028268
CIK 0001503802other
Filed
May 10, 8:00 PM ET
Accepted
May 11, 4:25 PM ET
Size
11.0 KB
Accession
0001209191-20-028268
Insider Transaction Report
Form 4
Primiano Christopher Brett
VP, Gen Counsel & Secretary
Transactions
- Sale
Common Stock
2020-05-07$19.62/sh−6,714$131,707→ 4,649 total - Exercise/Conversion
Common Stock
2020-05-07$6.54/sh+2,946$19,267→ 7,595 total - Sale
Common Stock
2020-05-07$20.00/sh−2,946$58,920→ 4,649 total - Exercise/Conversion
Stock Option (right to buy)
2020-05-07−2,946→ 10,054 totalExercise: $6.54Exp: 2026-01-14→ Common Stock (2,946 underlying)
Footnotes (4)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.37 to $20.00, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]Includes 996 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan.
- [F4]This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Documents
Issuer
Karyopharm Therapeutics Inc.
CIK 0001503802
Entity typeother
Related Parties
1- filerCIK 0001603510
Filing Metadata
- Form type
- 4
- Filed
- May 10, 8:00 PM ET
- Accepted
- May 11, 4:25 PM ET
- Size
- 11.0 KB